Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Tables)

v2.4.0.6
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2012
Abbott Biotherapeutics Corp [Member]
  
Milestone Payments Milestone Method [Line Items]  
Summary of milestone payment
Milestones
  
Payments
  
       
(1) when Company initiates a Phase I Clinical Trial of a licensed product
   $ 750,000  
(2) when Company initiates a Phase II Clinical Trial of a licensed product
     750,000  
(3) when Company initiates a Phase III Clinical Trial of a licensed product
     1,500,000  
(4) Biological License Application filing with U.S. FDA
     1,750,000  
(5) First commercial sale
     1,500,000  
(6) after the first $10,000,000 in net sales
     1,500,000  

MSKCC [Member]
  
Milestone Payments Milestone Method [Line Items]  
Summary of milestone payment
Milestones
  
Payments
  
       
1) filing of an New Drug Application (“NDA”) or regulatory approval
      
for each licensed product
   $ 750,000  
(2) upon the receipt of regulatory approval from the U.S. FDA for each
        
licensed product
     1,750,000